Fujifilm Biotechnologies' Holly Springs, NC facility has been chosen as one of seven participants in the FDA's PreCheck Pilot Program, aimed at strengthening US pharmaceutical manufacturing and regulatory readiness.
Biopharma has never lacked ambition. The gap has always been between scientific promise and a product on a shelf. That's exactly where the most consequential innovation is happening now.
Drug discovery generates enormous amounts of data, but turning it into meaningful insight is a major challenge.
Pharma 4.0 is high on every strategic agenda. Yet many struggle to turn digital ambitions into measurable results. Projects stall, systems don’t align, and valuable insights remain locked in fragmented data structures.
Recipharm announced a multi-million-dollar investment in its US operations, strengthening its ability to support pharma and biotech companies with advanced sterile fill and finish services.
Chiesi Group has completed its acquisition of KalVista Pharmaceuticals, marking the Italian biopharmaceutical group's largest deal to date.
Northway Biotech is finalizing the Baltic region's most advanced cell therapy center — a 3,500 m² facility at Vilnius City Innovation Industrial Park, set to open Q3 2025.
Precise, reproducible, and regulatory-ready: CE-based methods are redefining how scientists characterize therapeutic mAbs and ADCs across the biotherapeutic development pipeline.
Asahi Kasei Life Science has acquired the license rights for a novel antibody-drug conjugate (ADC) technology from The Noguchi Institute.
Catalent partners with non-profit Elpida Therapeutics to support late-phase AAV manufacturing for a rare neurological gene therapy, securing exclusive rights across Elpida's broader AAV pipeline.
New facility serves biopharma manufacturers throughout the region with local access to customer purification studies across Ecolab's Purolite Resin portfolio
In this CHEManager Leaders & Motivators interview, Frank Romanski, Lonza Capsugel, reflects on how strategy becomes execution and what resilience demands from teams,
Evonik is expanding its biotechnological production capacities at the Fermas site in Slovenská Ľupča with an investment of around €80 million
On Demand | Join biopharma professionals, CDMO leaders, and supply chain innovators for a virtual event exploring the future of outsourced biomanufacturing.
The acquisition marks Samsung Biologics’ geographical diversification, establishing its first US manufacturing presence and expanding regional client support.
AI and evolving regulations set to transform biopharma operations in drug development and quality.
At CPhI Frankfurt, Christene Smith of CHEManager International interviews Axplora CCO Arul Ramadurai on navigating industry uncertainty and building strategic partnerships.
Sandoz has announced the creation of a new biosimilar development, manufacturing and supply unit.
Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.
Forma Life Sciences launches as US-based contract development and manufacturing organization (CDMO) for oral solid dosage development and commercial manufacturing in Irvine, California.
As CROs and CDMOs expand their role in biopharma development and manufacturing, fast, accurate bioanalytic technologies remain critical to biotherapeutic affordability.
AsymBio, a subsidiary of Asymchem Group, has established integrated technology platforms including cell line development, upstream/downstream processing, conjugation toolbox, and analytics.
Fujifilm Biotechnologies expanded manufacturing and process development presence in the North East of England to support vital biomanufacturing of innovative medicines and vaccines in the United Kingdom.
WuXi Biologics partners with Sinorda on bispecific antibodies for autoimmune diseases and HanchorBio on fusion proteins for oncology and immunology.
On Demand | Tomorrow’s Biologics: Innovation, Intensification, and Precision in Cell Line & Upstream Processing
Fourth major US manufacturing investment announced this year, advancing AstraZeneca’s historic $50 billion commitment to medicines manufacturing and R&D.
New state-of-the-art facility in Philadelphia provides integrated lab and collaboration space along with tailored guidance to help move advanced therapies from early research to clinical readiness.
AGC Biologics has partnered with Rarity PBC to provide development and GMP manufacturing of a gene therapy aimed at treating a rare, life-threatening immune disorder.
Novartis plans to establish a flagship manufacturing hub in North Carolina by 2027-2028 as part of a $23 billion investment in US infrastructure.
SK Pharmteco has announced a $6.1 million investment to expand its Rancho Cordova, California, facility with new lab and kilo-scale capabilities for solid-phase peptide synthesis and purification.
Aenova will install an additional filling and manufacturing line at the Latina, Italy, site. This expansion is an important step to meet the increasing global demand for the production of biologics.
Following the acquisition of MCE Pharma Brenntag is building a unique position in both traditional pharma and biopharma.
Merck to acquire the chromatography business of JSR Life Sciences, a leading provider of CDMO services, preclinical and translational clinical research, and bioprocessing solutions.
Fujifilm Biotechnologies has opened one of North America's largest commercial-scale cell culture biomanufacturing sites in Holly Springs, North Carolina, US.
Dinamiqs, a Siegfried company specialized in viral vector design and manufacturing, inaugurated its new cGMP manufacturing facility.
